| A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation M Castroviejo‐Bermejo, C Cruz, A Llop‐Guevara, S Gutiérrez‐Enríquez, ... EMBO molecular medicine 10 (12), e9172, 2018 | 207 | 2018 |
| Homologous recombination repair deficiency and the immune response in breast cancer: a literature review B Pellegrino, A Musolino, A Llop-Guevara, V Serra, P De Silva, Z Hlavata, ... Translational oncology 13 (2), 410-422, 2020 | 70 | 2020 |
| Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making? B Pellegrino, J Mateo, V Serra, J Balmaña Esmo Open 4 (2), 2019 | 57 | 2019 |
| Metronomic chemotherapy for advanced breast cancer patients in the real world practice: final results of the VICTOR-6 study ME Cazzaniga, G Pinotti, E Montagna, D Amoroso, R Berardi, A Butera, ... The Breast 48, 7-16, 2019 | 55 | 2019 |
| Lung toxicity in non–small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature B Pellegrino, F Facchinetti, P Bordi, M Silva, L Gnetti, M Tiseo Clinical Lung Cancer 19 (2), e151-e161, 2018 | 54 | 2018 |
| Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification B Pellegrino, A Herencia-Ropero, A Llop-Guevara, F Pedretti, ... Cancer research 82 (8), 1646-1657, 2022 | 44 | 2022 |
| Luminal breast cancer: Risk of recurrence and tumor-associated immune suppression B Pellegrino, Z Hlavata, C Migali, P De Silva, M Aiello, K Willard-Gallo, ... Molecular Diagnosis & Therapy 25 (4), 409-424, 2021 | 40 | 2021 |
| Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review B Pellegrino, D Boggiani, C Tommasi, D Palli, A Musolino Acta Bio Medica: Atenei Parmensis 88 (3), 329, 2017 | 22 | 2017 |
| HER2-low status does not affect survival outcomes of patients with Metastatic Breast Cancer (MBC) undergoing first-line treatment with endocrine therapy plus palbociclib … F Carlino, A Diana, A Ventriglia, A Piccolo, C Mocerino, F Riccardi, ... Cancers 14 (20), 4981, 2022 | 19 | 2022 |
| Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer A Musolino, D Boggiani, B Pellegrino, D Zanoni, A Sikokis, G Missale, ... Critical Reviews in Oncology/Hematology 149, 102927, 2020 | 18 | 2020 |
| Oncologist burnout syndrome in Eastern Europe: results of the multinational survey D Kust, J Murgic, P Vukovic, I Kruljac, M Prpic, A Zilic, C Lengyel, ... JCO Oncology Practice 16 (4), e366-e376, 2020 | 18 | 2020 |
| Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial … B Pellegrino, L Cavanna, D Boggiani, C Zamagni, A Frassoldati, ... ESMO open 6 (1), 100019, 2021 | 17 | 2021 |
| Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient B Pellegrino, A Musolino, M Tiseo Annals of Oncology 28 (6), 1405-1406, 2017 | 17 | 2017 |
| Outcome and safety of sorafenib in metastatic renal cell carcinoma dialysis patients: a systematic review A Leonetti, M Bersanelli, B Castagneto, C Masini, G Di Meglio, ... Clinical Genitourinary Cancer 14 (4), 277-283, 2016 | 17 | 2016 |
| Prognostic risk factors for treatment decision in pT1a, b N0M0 HER2-positive breast cancers A Musolino, D Boggiani, A Sikokis, A Rimanti, B Pellegrino, R Vattiato, ... Cancer Treatment Reviews 43, 1-7, 2016 | 15 | 2016 |
| Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial ED Capoluongo, B Pellegrino, L Arenare, D Califano, G Scambia, ... ESMO open 7 (5), 100585, 2022 | 13 | 2022 |
| A review of immune checkpoint blockade in breast cancer B Pellegrino, C Tommasi, OE Cursio, A Musolino, E Migliori, P De Silva, ... Seminars in oncology 48 (3), 208-225, 2021 | 13 | 2021 |
| A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med. 2018 M Castroviejo-Bermejo, C Cruz, A Llop-Guevara, S Gutiérrez-Enríquez, ... Article e9172 View in Scopus, 2018 | 12 | 2018 |
| Long-term effects of breast cancer therapy and care: calm after the storm? C Tommasi, R Balsano, M Corianò, B Pellegrino, G Saba, F Bardanzellu, ... Journal of clinical medicine 11 (23), 7239, 2022 | 11 | 2022 |
| Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study B Pellegrino, M Bella, M Michiara, P Zanelli, N Naldi, R Porzio, B Bortesi, ... Acta Biomed 87 (1), 54-63, 2016 | 11 | 2016 |
